The current valuation score of Galmed Pharmaceuticals Ltd is 8.57, ranking 113 out of 387 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.24, which is -42.05% below the recent high of -0.14 and -7213.00% above the recent low of -17.44.
P/E
Relevant data have not been disclosed by the company yet.
P/B
Relevant data have not been disclosed by the company yet.
P/S
Relevant data have not been disclosed by the company yet.
P/CF
Relevant data have not been disclosed by the company yet.